Stapled Peptides Modulating HBV Replication via Host Factor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HBV antiviral therapeutics are limited in effectiveness as they primarily target the late stage replicative phase of the virus, and there is a lack of understanding of the precise host factors that drive early stage viral replication, making it challenging to inhibit HBV replication effectively.
Innovation Solution
The use of specific combinations of stapled peptides, such as Slug-ZF4s, Slug-ZF5s, Sox7-H1s, and Sox7-H2s, which are designed to target and inhibit host transcription factors like SNAI2 and SOX7, to modulate HBV replication by blocking key interactions at the HBV core promoter, thereby inhibiting HBV replication in cell lines and primary human hepatocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HBV antiviral therapeutics target the late stage replicative phase by inhibiting viral polymerase/reverse transcriptase, then viral load reduction is achieved, but effectiveness for viral clearance is limited
Solution Approach 1:
The patent applies preliminary action by targeting HBV replication at the early stage through host factor modulation. The stapled peptides interfere with host transcription factors (HNF4α, GCNF, FOXA2) before viral polymerase activation, preventing pre-genomic RNA synthesis and blocking replication upstream of the current therapeutic intervention point, thereby achieving more effective viral clearance
2Ease of manufacture
If host factors driving early stage viral replication are not well understood, then early stage replication cannot be effectively targeted, but understanding these factors is necessary for novel intervention approaches
Solution Approach 1:
The patent uses stapled peptides as intermediary molecules that bridge the gap between limited host factor knowledge and effective early stage intervention. These peptides mimic host transcription factors and bind to HBV core promoter elements, serving as surrogate tools to modulate early replication without requiring complete elucidation of all host-virus interaction mechanisms
Solution Approach 2:
The stapled peptides are designed as simplified copies or mimics of host transcription factors (particularly HNF4α). By replicating the DNA-binding functionality of these host factors in a stabilized peptide format, the invention enables early stage targeting using structurally simpler molecules that can be more easily designed and synthesized
Data Source
Figure 1
Figure 2
Figure 3a
AI summary
Presently disclosed is a method of modulating Hepatitis B virus (HBV) replication, by contacting the cell with at least one agent that modulates at least one factor from a specified group consisting of SNAI2, SOX7 and other factors, the screening of said agent and use thereof in a medicament for treating HBV infection or disease or condition associated with a HBV infection in a subject. In one preferred embodiment, the agent is one peptide derived from SOX7 or SNAI2 or stapled peptides thereof. As a separate invention, a method of identifying at least one factor that modulates replication of a virus is also disclosed.